Correlation between autoimmune markers and remission or thrombosis
| Marker . | Patients tested, n . | Marker positive, n (%) . | 95% CI for % positive . | Marker positive, remission, n (%) . | Marker negative, remission, n (%) . | P for remission* . | Marker positive, thrombosis, n (%) . | Marker negative, thrombosis, n (%) . | P for thrombosis* . |
|---|---|---|---|---|---|---|---|---|---|
| ANA | 144 | 94 (65) | 58-72 | 49 (52) | 25 (50) | .88 | 17 (18) | 0 (0) | .001 |
| Anti-ThyPeroxAb | 97 | 30 (31) | 24-38 | 9 (34) | 31 (59) | .017 | 2 (8) | 8 (15) | .08 |
| DAT | 120 | 35 (29) | 22-36 | 14 (40) | 47 (56) | .33 | 4 (11) | 10 (12) | .27 |
| ACL IgM | 125 | 20 (16) | 11-21 | 15 (75) | 50 (48) | .23 | 2 (10) | 15 (14) | .77 |
| ACL IgG | 122 | 16 (13) | 8-18 | 10 (63) | 53 (50) | .22 | 2 (13) | 15 (14) | .27 |
| LAC | 112 | 12 (11) | 6-15 | 4 (33) | 52 (52) | .64 | 5 (42) | 13 (13) | .005 |
| RF | 86 | 8 (9) | 4-14 | 4 (50) | 40 (51) | .87 | 1 (12.5) | 12 (15) | .70 |
| Marker . | Patients tested, n . | Marker positive, n (%) . | 95% CI for % positive . | Marker positive, remission, n (%) . | Marker negative, remission, n (%) . | P for remission* . | Marker positive, thrombosis, n (%) . | Marker negative, thrombosis, n (%) . | P for thrombosis* . |
|---|---|---|---|---|---|---|---|---|---|
| ANA | 144 | 94 (65) | 58-72 | 49 (52) | 25 (50) | .88 | 17 (18) | 0 (0) | .001 |
| Anti-ThyPeroxAb | 97 | 30 (31) | 24-38 | 9 (34) | 31 (59) | .017 | 2 (8) | 8 (15) | .08 |
| DAT | 120 | 35 (29) | 22-36 | 14 (40) | 47 (56) | .33 | 4 (11) | 10 (12) | .27 |
| ACL IgM | 125 | 20 (16) | 11-21 | 15 (75) | 50 (48) | .23 | 2 (10) | 15 (14) | .77 |
| ACL IgG | 122 | 16 (13) | 8-18 | 10 (63) | 53 (50) | .22 | 2 (13) | 15 (14) | .27 |
| LAC | 112 | 12 (11) | 6-15 | 4 (33) | 52 (52) | .64 | 5 (42) | 13 (13) | .005 |
| RF | 86 | 8 (9) | 4-14 | 4 (50) | 40 (51) | .87 | 1 (12.5) | 12 (15) | .70 |
Per logistic regression analysis, except ANA in thrombosis, per χ2 analysis.